Bioshares Number 873

Home » Media » Bioshares Number 873

Hexima CEO, Michael Aldridge, and Chief Operating Officer, Nicole van der Weerden, were recently interviewed by Bioshares. Michael and Nicole spoke to Bioshares about HXP124 and why it is well suited to onychomycosis, the encouraging efficacy results so far, our trial design and how we are working to make HXP124 a success.

Bioshares also asked Michael what he had been up to after leaving Peplin, until he joined Hexima in 2019.

View the Bioshares Number 873 article here Bioshares Number 873